The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.
Elia SeguíJuan Manuel TorresEdouard AuclinDavid CasadevallSara Peiro CarmonaJuan AguilarMarta García de HerrerosTeresa GorríaJuan Carlos LagunaMarta RodríguezAzucena GonzálezNicolas EpaillardJavier GaviraVictor BolañoJose Carlos TapiaMarco TagliamentoCristina TeixidóHugo ArasanzSara PilottoRafael López-CastroXabier Mielgo-RubioCristina UrbanoGonzalo RecondoMar Diaz PavonMaria Virginia BluthgenJosé Nicolas MinattaLorena LupinacciFara Brasó-MaristanyAleix PratAlexandru VlageaLaura MezquitaPublished in: Cancers (2024)
A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease.